5. All-in-one CGM and insulin pump from DexCom and Tandem Diabetes

Earlier this year, DexCom and Tandem Diabetes teamed up to develop a device that hopes to snag a big market share in the diabetes game: a combination continuous glucose monitor and insulin pump. Using Tandem's T:Slim touch-screen insulin pump as a platform, DexCom will bring its CGM knowhow to develop an all-in-one monitor-and-pump combo. And the benefits could be huge. There's just one combination device already on the market (Medtronic's ($MDT) Paradigm), but T:Slim is the world's smallest insulin pump and the only one with touch-screen controls. If DexCom and Tandem can keep the tech small and navigate the 510(k) process, their combination platform could be a hit in the diabetes world.

5. All-in-one CGM and insulin pump from DexCom and Tandem Diabetes
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.